Division of GlaxoSmithKline PLC
Latest From ViiV Healthcare
Topline results from the Phase III ATLAS-2M study indicate that injections every two months of ViiV/Janssen’s two-drug anti-HIV regimen are non-inferior to a once-monthly injectable regimen.
With EU submissions for once-monthly long-acting anti-HIV antivirals in hand, Janssen and ViiV appear to have set their sights on providing patients with more options.
First-in-class antiviral could be a potential backbone for combo regimens and entry into PrEP. New data releases at IAS highlight potential in both settings.
ViiV Healthcare research head tells Scrip she expects Dovato’s latest data presentation should boost the two-drug regimen’s uptake, and that the AIDS-fighter plans a US FDA filing of its investigational candidate fostemsavir before end-2019 following good Phase III BRIGHTE results.
- Therapeutic Areas
- Infectious & Viral Diseases
- GSK Pfizer HIV
- Western Europe
- Parent & Subsidiaries
- GlaxoSmithKline PLC
- Senior Management
Jerome Andries, CFO
John Pottage, MD, CSO & CMO
Gregory Reinaud, Head, Global Commercial Strategy
- Contact Info
Phone: (44) (0)20 8380 6200
980 Great West Rd.
Brentford, TW8 9GS
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.